Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

By A. Zietman, M. Desilvio, J. Slater, C. Rossi, Daniel W. Miller, J. Adams, W. Shipley. Journal of the American Medical Association (JAMA), 2005

1,278 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Guideline for the management of clinically localized prostate cancer: 2007 update. (2007, methodology): “2 Gy, using a combination of photon and proton beams.(35) At five years, there was no difference in overall survival, but the higher-dose therapy conferred a 49% reduction in the risk of biochemical failure (p<0.”
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. (2008, methodology): “There has been no significant difference in GU toxicity greater than grade 2 or grade 3 between dose levels in any of the randomized studies (19, 20).”
Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. (2010, background): “2 Gy) and was first reported with 5-year follow-up.(7) At that time it showed an advantage to dose escalation for low-risk patients without any increase in serious late rectal or urinary morbidity.”
Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer (2008, background): “2 Gy) EBRT (1 RCT) [21] Medium Trial 1: Overall mortality/survival: No difference between conventional and high-dose EBRT Trial 1: Disease-specific survival: No difference Trial 1: Biochemical/clinical progression or recurrence: High-dose therapy was more effective than conventional therapy in contr”